Delivery Order SPE2DB20D9331-SPE2DB25FL1M2

Award Date 6/26/25
Potential Completion Date 7/18/25
Potential Value $5.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,073.48 contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML. The order has a period of performance through June 30, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML medical supplies, with a ceiling value of $1,691.16 and a performance period through May 30, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,634.04, was awarded by the Defense Logistics Agency (DLA) and has an ultimate completion date of June 18, 2024. The contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, which is a pharmaceutical product. DMS Pharmaceutical Group Inc. has an Indefinite Delivery Contract (IDC) with...
This is a firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The contract is for the supply of "VISIONBLUE 0.06% SYRINGE 0.5ML" medical products, with a ceiling value of $1,691.16 and a performance period through July 8, 2025. DMS Pharmaceutical Group is an established pharmaceutical wholesaler that has secured a significant Indefinite Delivery Contract (IDC) with the DLA, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,634.04 contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a specialized pharmaceutical product. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which allows the DLA to...
This is a Firm Fixed Price Delivery Order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $6,536.16, is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a specialized pharmaceutical product, with a period of performance through December 6, 2024. This order is issued under a larger Indefinite Delivery Contract (IDC) with a ceiling value of...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is valued at $2,536.74 and covers the delivery of the VISIONBLUE 0.06% SYRINGE 0.5ML product. The contract has an ultimate completion date of April 29, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of pharmaceutical products and medical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,556.54, is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of December 15, 2023 and was awarded on November 24, 2023. DMS Pharmaceutical Group Inc. is the prime contractor for this award. The company specializes...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $1,691.16, is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML medical supplies. The contract has a completion date of May 9, 2025. DMS Pharmaceutical Group Inc. is a critical supplier in the federal pharmaceutical supply chain, holding a $499,999,999 Indefinite Delivery Contract...
This firm-fixed-price delivery order was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA). The contract is for the delivery of VISIONBLUE 0.06% SYRINGE 0.5ML, a specialized pharmaceutical product, with a ceiling value of $1,691.16. The contract is not associated with any set-aside designation. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the...
  • SPE2DB20D9331
    Indefinite Delivery Contract
  • SPE2DB20D9331-SPE2DB25FL1M2
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of VISIONBLUE 0.06% SYRINGE 0.5ML, with a ceiling value of $5,073.48 and an ultimate completion date of July 18, 2025. This award is not associated with a set-aside program. DMS Pharmaceutical Group Inc. has a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide.

Generated 9/25/25, 10:52 AM